Skip to main content

Advertisement

ADVERTISEMENT

Conference Coverage

Conference Coverage
05/03/2021
Journal of Clinical Pathways
Conference Coverage
05/03/2021
Journal of Clinical Pathways
Conference Coverage
04/29/2021
Journal of Clinical Pathways

Advertisement

Conference Coverage
04/29/2021
Journal of Clinical Pathways
Conference Coverage
04/22/2021
JCP Editors
Real-World Tolerability of PARP Inhibitors for Ovarian Cancer in the United States A study presented at the virtual 2021 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer compared the...
Real-World Tolerability of PARP Inhibitors for Ovarian Cancer in the United States A study presented at the virtual 2021 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer compared the...
...
04/22/2021
Journal of Clinical Pathways
Conference Coverage
04/16/2021
Study results show that immunotherapy is the most common next line of therapy after discontinuation of an EGFR-TKI and platinum-based chemotherapy for metastatic NSCLC.
Study results show that immunotherapy is the most common next line of therapy after discontinuation of an EGFR-TKI and platinum-based chemotherapy for metastatic NSCLC.
Study results show that...
04/16/2021
Journal of Clinical Pathways

Advertisement

Conference Coverage
04/07/2021
Journal of Clinical Pathways
Conference Coverage
04/07/2021
Treatment guided by biomarker testing is associated with improved survival outcomes in patients with advanced or metastatic NSCLC.
Treatment guided by biomarker testing is associated with improved survival outcomes in patients with advanced or metastatic NSCLC.
Treatment guided by biomarker...
04/07/2021
Journal of Clinical Pathways
Conference Coverage
04/06/2021
Journal of Clinical Pathways

Advertisement

Conference Coverage
03/30/2021
Journal of Clinical Pathways

Advertisement